Immunome, Inc.
IMNM
$7.91
$0.7410.32%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 13.37% | -984.00% | -550.03% | -2,932.60% | -1,089.75% |
| Total Depreciation and Amortization | 131.52% | 243.98% | 328.66% | 77.70% | -1.15% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -61.00% | 615.55% | 789.35% | 9,179.00% | 6,013.73% |
| Change in Net Operating Assets | 166.74% | 138.24% | 320.22% | -83.44% | -1,447.46% |
| Cash from Operations | -140.91% | -296.64% | -312.79% | -146.21% | -161.24% |
| Capital Expenditure | -293.98% | -132,191.67% | -589.41% | -1,941.51% | -384.72% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 128.60% | -- | -- | -- | -- |
| Cash from Investing | 132.52% | 67,038.89% | -23,925.88% | -35,023.58% | -41,569.44% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5,421.56% | -- | -- | 686,958.82% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.73% | -100.34% | -- | -- | -- |
| Cash from Financing | -63.81% | -99.50% | -- | 645,326.47% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -251.99% | -118.70% | -1,637.53% | 609.70% | 218.99% |